Zanidatamab

monoclonal antibody

Identifier: CI-DRUG-00000772
Entity page: /drug/zanidatamab ↗
Edges: 82

Neighbours: 18 cancers1 genes10 trials3 approvals
Drawn: 32 of 32 neighbours (cap 60); table lists every fetched edge

Accepted: cancer:<slug>, gene:<symbol>, variant:<slug>, drug:<slug>, trial:<NCT id>, or a bare CI id. Find slugs with search.

Most connectedLung Non-Small Cell Carcinoma 3,147 Malignant Colorectal Neoplasm 1,866 ABL1 298 EGFR 276 Imatinib 450 Dasatinib 321

Neighbourhood

Radial view

Focus at the centre; neighbours grouped by entity type. Click a node to re-centre the graph on it; ↗ opens the entity page. Hover a spoke for relationship, evidence level, cancer context and source.

Edges

Every edge, grouped by relationship

Source-native edges first (aggregated per neighbour, direction, evidence level and source), then derived registry links. Up to 15 per relationship (10 trials); “show all” raises one group to 200.

Relationship	Neighbour	Direction	Evidence level	Cancer context	Support	Claim	Source	Expand
Zanidatamab approved for …APPROVED_FOR6 of 3
→ approved for	Malignant Biliary Tract Neoplasmsubtype	supports	FDA ORIG	Malignant Biliary Tract Neoplasm	1	Regulatory	openfda	graph →
→ approved for	Esophageal Adenocarcinomasubtype	supports

Zanidatamab targets …TARGETS1 of 1
→ targets	ERBB2	—	INHIBITOR	—	1	Curated	chembl	graph →

Zanidatamab targets …TARGETS1 of 1

→ targets

ERBB2

—

INHIBITOR

—

Curated

Zanidatamab investigated for …INVESTIGATED_FOR4 of 4
→ investigated for	Neoplasmcancer_family	unknown	4	Neoplasm	1	Curated	chembl	graph →
→ investigated for	Breast Neoplasmcancer_family	unknown	3	Breast Neoplasm	1	Curated	chembl	graph →
→ investigated for	Angiosarcomasubtype	unknown	2	Angiosarcoma	1	Curated	chembl	graph →
→ investigated for	Gastric Neoplasmcancer_family	unknown	2	Gastric Neoplasm	1	Curated	chembl	graph →

Zanidatamab investigated in trials for …INVESTIGATED_IN_TRIALSderived15 of 45show all (up to 200)
→ investigated in trials for	Malignant Breast Neoplasm 8 trials (7 active) · conditions mapped to this cancer only (no hierarchy roll-up)	—	—	Malignant Breast Neoplasm	8	Observed	clinicaltrials	graph →
→ investigated in trials for	HER2-Positive Breast Carcinoma 4 trials (4 active) · conditions mapped to this cancer only (no hierarchy roll-up)	—	—	HER2-Positive Breast Carcinoma	4	Observed	clinicaltrials	graph →
→ investigated in trials for	Malignant Colorectal Neoplasm 4 trials (4 active) · conditions mapped to this cancer only (no hierarchy roll-up)	—	—	Malignant Colorectal Neoplasm	4	Observed	clinicaltrials	graph →
→ investigated in trials for	Malignant Gastric Neoplasm 4 trials (3 active) · conditions mapped to this cancer only (no hierarchy roll-up)	—	—	Malignant Gastric Neoplasm	4	Observed	clinicaltrials	graph →
→ investigated in trials for	Breast Neoplasmcancer_family 3 trials (2 active) · conditions mapped to this cancer only (no hierarchy roll-up)	—	—	Breast Neoplasm	3	Observed	clinicaltrials	graph →
→ investigated in trials for	Colorectal Neoplasm 3 trials (3 active) · conditions mapped to this cancer only (no hierarchy roll-up)	—	—	Colorectal Neoplasm	3	Observed	clinicaltrials	graph →
→ investigated in trials for	Malignant Rectal Neoplasm 3 trials (3 active) · conditions mapped to this cancer only (no hierarchy roll-up)	—	—	Malignant Rectal Neoplasm	3	Observed	clinicaltrials	graph →
→ investigated in trials for	Colorectal Carcinoma 2 trials (2 active) · conditions mapped to this cancer only (no hierarchy roll-up)	—	—	Colorectal Carcinoma	2	Observed	clinicaltrials	graph →
→ investigated in trials for	Esophageal Adenocarcinomasubtype 2 trials (2 active) · conditions mapped to this cancer only (no hierarchy roll-up)	—	—	Esophageal Adenocarcinoma	2	Observed	clinicaltrials	graph →
→ investigated in trials for	Gastroesophageal Junction Adenocarcinoma 2 trials (2 active) · conditions mapped to this cancer only (no hierarchy roll-up)	—	—	Gastroesophageal Junction Adenocarcinoma	2	Observed	clinicaltrials	graph →
→ investigated in trials for	HER2-Positive Gastric Adenocarcinoma 2 trials (2 active) · conditions mapped to this cancer only (no hierarchy roll-up)	—	—	HER2-Positive Gastric Adenocarcinoma	2	Observed	clinicaltrials	graph →
→ investigated in trials for	Lung Non-Small Cell Carcinoma 2 trials (2 active) · conditions mapped to this cancer only (no hierarchy roll-up)	—	—	Lung Non-Small Cell Carcinoma	2	Observed	clinicaltrials	graph →
→ investigated in trials for	Malignant Biliary Tract Neoplasmsubtype 2 trials (2 active) · conditions mapped to this cancer only (no hierarchy roll-up)	—	—	Malignant Biliary Tract Neoplasm	2	Observed	clinicaltrials	graph →
→ investigated in trials for	Malignant Colon Neoplasm 2 trials (2 active) · conditions mapped to this cancer only (no hierarchy roll-up)	—	—	Malignant Colon Neoplasm	2	Observed	clinicaltrials	graph →
→ investigated in trials for	Malignant Endometrial Neoplasm 2 trials (1 active) · conditions mapped to this cancer only (no hierarchy roll-up)	—	—	Malignant Endometrial Neoplasm	2	Observed	clinicaltrials	graph →

Zanidatamab studied in …STUDIED_INderived10 of 29show all (up to 200)
→ studied in	NCT05868226Phase 1/Phase 2 · recruiting PRE-ISPY Phase I/II Oncology Platform Program · 29 trials list this drug (20 active)	—	—	Neoplasm,Malignant Neoplasm,Solid Neoplasm+2	1	Observed	clinicaltrials	graph →
→ studied in	NCT06324357Phase 1/Phase 2 · recruiting Beamion BCGC-1: A Study to Find a Suitable Dose of Zongertinib Used Alone and in Combination With Other Treatments to Test Whether it Helps People With Different Types of HER2+ Cancer That Has Spread · 29 trials list this drug (20 active)	—	—	Malignant Breast Neoplasm,Esophageal Adenocarcinoma,Gastric Adenocarcinoma+2	1	Observed	clinicaltrials	graph →
→ studied in	NCT07841873Phase 2 · not yet recruiting Zanidatamab Combined With Liposomal Irinotecan and Capecitabine for Second-line Treatment of HER2-positive Unresectable Biliary Tract Tumors · 29 trials list this drug (20 active)	—	—	Malignant Biliary Tract Neoplasm	1	Observed	clinicaltrials	graph →
→ studied in	NCT04224272Phase 2 · completed Phase 2a Study of ZW25 in Combination With Palbociclib Plus Fulvestrant · 29 trials list this drug (20 active)	—	—	Breast Neoplasm	1	Observed	clinicaltrials	graph →
→ studied in	NCT05152147Phase 3 · active not recruiting A Study of Zanidatamab in Combination With Chemotherapy Plus or Minus Tislelizumab in Patients With HER2-positive Advanced or Metastatic Gastric and Esophageal Cancers · 29 trials list this drug (20 active)	—	—	Gastric Neoplasm,Esophageal Adenocarcinoma	1	Observed	clinicaltrials	graph →
→ studied in	NCT06282575Phase 3 · recruiting Efficacy and Safety of Zanidatamab With Standard-of-care Therapy Against Standard-of-care Therapy for Advanced HER2-positive Biliary Tract Cancer · 29 trials list this drug (20 active)	—	—	Malignant Biliary Tract Neoplasm	1	Observed	clinicaltrials	graph →
→ studied in	NCT04276493Phase 1/Phase 2 · completed Anti-HER2 Bispecific Antibody Zanidatamab (ZW25) Activity in Combination With Chemotherapy With/Without Tislelizumab · 29 trials list this drug (20 active)	—	—	Malignant Breast Neoplasm,Malignant Gastric Neoplasm	1	Observed	clinicaltrials	graph →
→ studied in	NCT07102381Phase 2 · recruiting A Phase 2 Neoadjuvant Study of Zanidatamab in Combination With Chemotherapy in Participants With HER2-positive Breast Cancer · 29 trials list this drug (20 active)	—	—	Malignant Breast Neoplasm,HER2-Positive Breast Carcinoma	1	Observed	clinicaltrials	graph →
→ studied in	NCT07780968not yet recruiting Zanidatamab Outcomes and Lived Experiences in Advanced HER2+ GEA · 29 trials list this drug (20 active)	—	—	Malignant Esophageal Neoplasm,Malignant Gastric Neoplasm,HER2-Positive Gastric Adenocarcinoma	1	Observed	clinicaltrials	graph →
→ studied in	NCT05035836Phase 2 · recruiting A Phase 2 Single-Arm Open-Label Pilot Trial Evaluating Zanidatamab (ZW25) in Patients With Early Stage HER2/Neu Positive (HER2+) Breast Cancer (BC) · 29 trials list this drug (20 active)	—	—	Malignant Breast Neoplasm	1	Observed	clinicaltrials	graph →

Radial view

Every edge, grouped by relationship

Paths